Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Victoria Foy"'
Autor:
Daniel Netto, Melissa Frizziero, Victoria Foy, Mairéad G. McNamara, Alison Backen, Richard A. Hubner
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5206-5223 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of i
Externí odkaz:
https://doaj.org/article/82cdbede92d547bc8b5e3d4f02cac346
Autor:
Victoria Foy, Mairéad G. McNamara, Juan W. Valle, Angela Lamarca, Julien Edeline, Richard A. Hubner
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8665-8685 (2023)
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint
Externí odkaz:
https://doaj.org/article/e6075971c8d843248347bb5a70df88af
Autor:
Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor, Javier Gallego
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) an
Externí odkaz:
https://doaj.org/article/cf85aa4387664f46bdb19d331cc85d54
Autor:
Francesca Chemi, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Alicia-Marie Conway, Sophie A. Richardson, Katarzyna Kamieniecka, Rebecca Caeser, Daniel J. White, Sumitra Mohan, Victoria Foy, Kathryn L. Simpson, Melanie Galvin, Kristopher K. Frese, Lynsey Priest, Jacklynn Egger, Alastair Kerr, Pierre P. Massion, John T. Poirier, Gerard Brady, Fiona Blackhall, Dominic G. Rothwell, Charles M. Rudin, Caroline Dive
Publikováno v:
Nature Cancer. 3:1260-1270
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor expression have been defined that, in mouse models and cell lines, exhibit potential diff
Autor:
Fabiola Fernandez-Gutierrez, Caroline Dive, Alessandro Morabito, T. Jeroen N. Hiltermann, Colin R Lindsay, Benjamin Besse, Fiona H Blackhall, Harry J.M. Groen, Francesco Perrone, Françoise Farace, Nicola Normanno, Victoria Foy, Andrew G Renehan, Mathew Carter, Matthew G Krebs, Lynsey Priest, Leon W.M.M. Terstappen, Alexandra Carmel, Corinne Faivre-Finn, Elisabetta Rossi, Stefan Michiels, Antonella De Luca
Publikováno v:
Foy, V, Lindsay, C R, Carmel, A, Fernandez-Gutierrez, F, Krebs, M G, Priest, L, Carter, M, Groen, H J M, Hiltermann, T J N, de Luca, A, Farace, F, Besse, B, Terstappen, L, Rossi, E, Morabito, A, Perrone, F, Renehan, A, Faivre-Finn, C, Normanno, N, Dive, C, Blackhall, F & Michiels, S 2021, ' EPAC-lung : European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer ', Translational Lung Cancer Research, vol. 10, no. 4, pp. 1653-1665 . https://doi.org/10.21037/tlcr-20-1061
Translational Lung Cancer Research, 10(4), 1653-1665. Society for Translational Medicine (STM)
Translational lung cancer research, 10(4), 1653-1665. AME PUBL CO
Transl Lung Cancer Res
Translational Lung Cancer Research, 10(4), 1653-1665. Society for Translational Medicine (STM)
Translational lung cancer research, 10(4), 1653-1665. AME PUBL CO
Transl Lung Cancer Res
Background: Circulating tumour cell (CTC) number is an independent prognostic factor in patients with small cell lung cancer (SCLC) but there is no consensus on the CTC threshold for prognostic significance. We undertook a pooled analysis of individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f509aaeef7492549a632754ed75925f2
https://doi.org/10.21037/tlcr-20-1061
https://doi.org/10.21037/tlcr-20-1061
Autor:
Lynsey Priest, Fiona H Blackhall, Fabiola Fernandez-Gutierrez, Corinne Faivre-Finn, Jacqueline Pierce, Linda Ashcroft, Katy Burns, Rebecca Tay, Karen Morris, Jonathan Tugwood, Colin R Lindsay, Victoria Foy, Caroline Dive
Publikováno v:
Tay, R Y, Fernández-gutiérrez, F, Foy, V, Burns, K, Pierce, J, Morris, K, Priest, L, Tugwood, J, Ashcroft, L, Lindsay, C R, Faivre-finn, C, Dive, C & Blackhall, F 2019, ' Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz122
The clinical significance of circulating tumour cells (CTCs) in limited-stage small-cell lung cancer (LS-SCLC) is not well defined. We report a planned exploratory analysis of the prevalence and prognostic value of CTCs in LS-SCLC patients enrolled w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8f7a64eb0da41234c1058673b8b4a1
https://research.manchester.ac.uk/en/publications/92a55d00-61ab-486e-afd6-3b7e20f3bd85
https://research.manchester.ac.uk/en/publications/92a55d00-61ab-486e-afd6-3b7e20f3bd85
Autor:
Nigel K Smith, Hui Sun Leong, Fiona H Blackhall, Mahmood Ayub, Tine Descamps, Mathew Carter, Dominic G. Rothwell, Crispin J. Miller, Sumitra Mohan, Pieta Schofield, Bedirhan Kilerci, Victoria Foy, Caroline Dive, T. Hedley Carr, Lynsey Priest, Cong Zhou, Sudhakar Sahoo, Gerard Brady, Corinne Faivre-Finn
Publikováno v:
Mohan, S, Foy, V & Ayub, M 2020, ' Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC ', Journal of Thoracic Oncology, vol. 15, no. 2, pp. 216-230 . https://doi.org/10.1016/j.jtho.2019.10.007
Journal of Thoracic Oncology
Journal of Thoracic Oncology
IntroductionSCLC accounts for approximately 250,000 deaths worldwide each year. Acquisition of adequate tumor biopsy samples is challenging, and liquid biopsies present an alternative option for patient stratification and response monitoring.MethodsW
Autor:
Fabio Gomes, Fiona H Blackhall, Kristopher K. Frese, Katie Baker, Martin Forster, Maximilian W Schenk, Alice Lallo, Victoria Foy, Caroline Dive
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has been no change to the stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d985075e4d708fa0a6f83fb0013005
https://hdl.handle.net/10400.17/2823
https://hdl.handle.net/10400.17/2823
Autor:
Victoria Foy, Fiona H Blackhall, Caroline Dive, Corinne Faivre-Finn, Fabiola Fernandez-Gutierrez
Publikováno v:
Foy, V, Fernandez-Gutierrez, F, Faivre-Finn, C, Dive, C & Blackhall, F 2017, ' The clinical utility of circulating tumour cells in patients with small cell lung cancer ', Translational Lung Cancer Research, vol. 6, no. 4, pp. 409 . https://doi.org/10.21037/tlcr.2017.07.05, https://doi.org/10.21037%2Ftlcr.2017.07.05
Small cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50abbf424ea4f8af103296cdc7ec5d5d
https://europepmc.org/articles/PMC5583068/
https://europepmc.org/articles/PMC5583068/
Autor:
Lynsey Priest, Fiona H Blackhall, S. Mohan, H.S. Leong, Gerard Brady, Corinne Faivre-Finn, Dominic G. Rothwell, Victoria Foy, M. Carter, Caroline Dive
Publikováno v:
ESMO Open. 3:A4-A5
Introduction Analysis of circulating cell-free DNA (cfDNA) and circulating tumour cells (CTCs) obtained from the peripheral blood of patients with cancer is a powerful and minimally invasive approach that allows the reconstruction of tumour genomes,